Japan medical devices 2026: aging-cohort demand and the FY2026 reimbursement reform
Japan's medical devices market reached roughly JPY 6.0 trn (USD ~40 bn) in 2023 [MHLW 2024] — the world's third-largest — with demand structurally underwritten by the oldest population on earth: 36.3 million people aged 65+, 29.3% of the total [Govt stats 2024]. The FY2026 reimbursement reform pairs a +3.09% fee-body increase with the first-ever reverse-margin correction, redrawing device economics just as the aging cohort enters its highest-utilisation decade [Chuikyo 2025].
Executive summary
Japan is the world's third-largest medical device market at approximately $40 billion. The market is characterised by conservative procurement processes, lengthy regulatory approval timelines under PMDA, and strong preference for relationship-based sales through specialised distributors. US and European multinationals dominate capital equipment segments, while domestic players (Terumo, Olympus, Hoya) lead in specialty devices — notably endoscopy, where Olympus has 70%+ global market share. Japan's ageing population (29% over 65) is the primary structural demand driver. Recent regulatory reforms have aimed to reduce the "device lag" — the historically significant gap between US/EU approval and Japanese market entry. This report covers Japan's medical device market by segment, PMDA regulatory pathway, distribution channel structure, competitive landscape, and demand outlook driven by demographic ageing through 2026.
Report details
- Published
- 2026-06-01
- Pages
- 14
- Format
- Code
- JP-MDV-XPL-D26-01
- Market
- Japan
- Industry
- Medical Devices
- Year
- 2026
Table of contents · 12 sections
- 01 Executive summary
- 02 Strategic implications
- 03 Market sizing and segments
- 04 Segment economics
- 05 Aging-cohort demand structure
- 06 FY2026 reimbursement reform
- 07 Reimbursement policy timeline
- 08 Device lag and price gap
- 09 Competitive landscape
- 10 SaMD and AI devices
- 11 5-year outlook and forecast
- 12 Methodology and sources
The full report is available to subscribers and buyers. The executive summary above is free to read.